TICKERNERD
Menu
APYXAPYXHealthcare · Medical Devices

APYX Stock Forecast: Apyx Medical Corp. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$2.60
−3.35% on the day

The 6 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +130.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$109.5M
Ticker Nerd rank
69/ 100
Median analyst target
$6.00
Analysts covering
6
Revenue$13.9M+22.1% y/y
Operating income−$1.8M
Net income−$3.1M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.7%
1M
+6.1%
YTD
−25.7%
1Y
−11.9%
From 52W high
−46.5%
From 52W low
+10.2%
$2.36
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
69/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
73
Quality
72
Revisions
68
Momentum
62
Volatility
60
Value
54
Issuance
28
Accruals
27

Growth (86): Sales and profits are climbing, and climbing faster than before.

Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26APYXHigh $8.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $6.00Median $6.00High $8.00

The green dot is the last close — the median target sits +130.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026Maxim GroupInitiatesBuy$6.00
13 July 2026HC Wainwright & Co.InitiatesBuy$7.00
13 July 2026HC Wainwright & Co.InitiatesBuy—
11 Mar 2026BTIGUpgradeBuy—
11 Mar 2026Craig-HallumMaintainsBuy—
16 Dec 2025Roth CapitalInitiatesBuy—
12 Nov 2025CitizensUpgradeMarket Outperform—
17 Oct 2024BTIGInitiatesNeutral—
16 Sept 2024JMP SecuritiesReiteratesMarket Perform—
10 Nov 2023Stephens & Co.MaintainsOverweight—
11 Aug 2023Piper SandlerMaintainsOverweight—
14 July 2023Stephens & Co.InitiatesOverweight—
15 June 2023Lake StreetMaintainsBuy—
24 May 2023JMP SecuritiesReiteratesMarket Perform—
12 May 2023Lake StreetMaintainsBuy—
8 Dec 2022Lake StreetAssumesBuy$5.00
12 Aug 2022Piper SandlerMaintainsOverweight—
19 July 2022Lake StreetMaintainsBuy—
20 May 2022Lake StreetInitiatesBuy—
13 Aug 2021JMP SecuritiesMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

APYX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Apyx Medical Corp. returned −11.9% against +12.4% for the S&P 500, dividends included.

APYX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26APYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Apyx Medical Corp. (APYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.6×

Cheaper than 93% of US stocks

Price / sales
1.9×

Cheaper than 53% of US stocks

Price / book
10.3×

Cheaper than 8% of US stocks

EV / EBITDA
−44.3×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
22.1%

Higher than 71% of US stocks

Earnings growth (YoY)
22.1%

Higher than 61% of US stocks

Gross margin
63.9%

Higher than 77% of US stocks

Operating margin
−13.0%

Higher than 23% of US stocks

Net margin
−14.8%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−90.7%

Higher than 14% of US stocks

Return on assets
−3.7%

Higher than 34% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apyx Medical Corp. (APYX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apyx Medical Corp. has a market value of $109.5M and an enterprise value of $122.0M.

  • Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 22.1% year on year.

  • Net income over the same four quarters: −$8.4M, a −14.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$11.0M.

  • Shares outstanding: 42.1M.

  • Trailing P/E: −9.6×; forward P/E: −10.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Apyx Medical Corp. employs 205 people — $285K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

APYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
APYXApyx Medical Corp.$109.5M69
OWLTOwlet, Inc.$117.5M41
LUNGPulmonx Corp.$123.9M89
CATXPerspective Therapeutics, Inc.$131.0M22
QTRXQuanterix Corp.$136.8M39
LUCDLucid Diagnostics, Inc.$82.2M36
SERASera Prognostics, Inc.$79.9M43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APYX news & analysis

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)

PRNewsWire · 22 Oct 2026negative

Purcell & Lefkowitz LLP announced an investigation of Apyx Medical on behalf of shareholders. It seeks to determine whether the company's directors breached fiduciary duties in connection with recent corporate actions.

Why it matters — The investigation concerns the conduct of Apyx Medical's directors and recent corporate actions, matters of interest to APYX shareholders.

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

GlobeNewsWire · 21 Oct 2026neutral

Apyx Medical announced that management will participate in the UBS Global Healthcare Conference on November 9–11, 2026, in Miami. Management plans a fireside chat at 10:15 a.m. ET on November 9 and one-on-one investor meetings that day.

Why it matters — The event provides an opportunity for investors to hear from Apyx Medical management and meet with them.

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

GlobeNewsWire · 29 Sept 2026positive

Apyx Medical announced results from a prospective clinical study evaluating the effects of its Renuvion helium plasma radiofrequency technology on biological markers of skin quality.

Why it matters — The study results provide new clinical data supporting the efficacy of Renuvion, a core product in Apyx's surgical aesthetics portfolio.

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

MarketBeat · 12 Aug 2026positive

Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Why it matters — Apyx watchers would care because the company is framing its aesthetic-device lineup as a beneficiary of the GLP-1 weight-loss trend driving demand for body-contouring procedures.

FAQ

Frequently asked questions about APYX stock

What is the APYX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APYX stock a buy right now?

Of the 6 analysts covering Apyx Medical Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 69 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APYX?

As at 31 Oct 2026, Apyx Medical Corp. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will APYX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +130.8% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 69 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APYX stock forecast for 2030?

No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.

How has APYX stock performed over the past year?

Apyx Medical Corp. returned -11.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apyx Medical Corp. do?

Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures.

What is the latest news on APYX?

The most recent item we track (PRNewsWire, 22 Oct 2026): "SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)". Purcell & Lefkowitz LLP announced an investigation of Apyx Medical on behalf of shareholders. It seeks to determine whether the company's directors breached fiduciary duties in connection with recent corporate actions.

Company

About Apyx Medical Corp.

Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures. Its products are used by physicians, surgery centers, hospitals, and other healthcare providers across surgical aesthetics and broader electrosurgical applications. Apyx Medical Corporation also serves original equipment manufacturing customers with engineered medical devices and components. Headquartered in Clearwater, Florida, Apyx Medical Corporation focuses on tools that combine energy delivery and surgical performance for modern operating environments.

CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com